PharmaSGP Holding SE: insider trades · Germany · BaFin

About PharmaSGP Holding SE

PharmaSGP Holding SE is a German consumer-health company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany. The group focuses on the development, marketing and distribution of over-the-counter (OTC) medicines and consumer health products, with a portfolio geared toward chronic and recurring conditions, especially pain, sleep disorders and selected age-related ailments. PharmaSGP is structured as a holding company and does not run a direct third-party commercial business itself; instead, it oversees operating subsidiaries including PharmaSGP GmbH, Remitan GmbH, Restaxil GmbH, Fokusan Health GmbH and PharmaSGP Vitalmed GmbH, all located in Gräfelfing near Munich. This gives the company a clear German operational base and places it within one of Europe’s most established pharmaceutical and health-focused ecosystems. PharmaSGP’s roots lie in building an OTC brand platform, and the group has evolved into a branded consumer-health holding since the current structure was launched in May 2020. Its business model is built around strong brands, portfolio profitability and a growth strategy that combines organic expansion with targeted acquisitions of brands, approvals and product portfolios. At year-end 2024, the group said it had nearly 50 OTC medicines and other health products. Key brands include Restaxil® and RubaXX® for nerve pain and rheumatic pain, TAUMEA® for dizziness, and DESEO® and Neradin® in sexual-wellness related categories. The 2021 acquisition of Baldriparan®, Formigran®, Spalt® and Kamol® broadened the portfolio into sleep, migraine and analgesic categories. In Germany, PharmaSGP highlights leadership positions in certain OTC niches, including non-chemical pain relief products and Baldriparan® as a leading herbal sleep aid. Geographically, the company remains primarily Germany-centric, while also aiming to scale its branded OTC platform across Europe. Its strategy is to leverage recognizable brands, pharmacy-driven distribution and focused consumer marketing to build sustainable revenue streams and expand its footprint. Recent notable events include a public share repurchase offer approved in 2024 for up to 594,405 shares, the publication of its 2024 annual report in spring 2025, and a management change: Peter Gerckens became CEO effective January 1, 2025 after Natalie Weigand did not renew her mandate. For French-speaking investors, PharmaSGP offers a defensive healthcare exposure with a branded OTC model, a German domicile, disciplined capital allocation and a clear focus on shareholder value creation.